Sulfonylureas: a new look at old therapy (Q38190489)

30 August 2017

1 reference

title

Sulfonylureas: a new look at old therapy (English)

1 reference

30 August 2017

Peter M Thulé

1

1 reference

PubMed ID

24563333

30 August 2017

Guillermo Umpierrez

series ordinal

2

1 reference

30 August 2017

1 April 2014

1 reference

30 August 2017

Current diabetes report

1 reference

30 August 2017

14

1 reference

30 August 2017

473

1 reference

30 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1007/s11892-014-0473-5

30 August 2017

0 references

cites work

Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 2.

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Insulin secretion as studied on isolated perfused rat pancreas. I. Synergism between glucose and hypoglycaemic sulphonamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

21 January 2018

Oral hypoglycemic agents

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Efficacy and safety of oral hypoglycemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Oral therapies for diabetic hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

The sulfonylurea receptor, an atypical ATP-binding cassette protein, and its regulation of the KATP channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Sulfonylurea action re-revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

ATP-sensitive potassium channelopathies: focus on insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Direct activation of Epac by sulfonylurea is isoform selective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Epac2: a sulfonylurea receptor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

The sulfonylurea glyburide induces impairment of glucagon and growth hormone responses during mild insulin-induced hypoglycemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Stimulatory effects of tolbutamide infusion on plasma glucagon in insulin-dependent diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events: A comparison of glyburide with other secretagogues and with insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Severe hypoglycemia and risks of vascular events and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Systematic review: glucose control and cardiovascular disease in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Decreasing postprandial C-peptide levels over time are not associated with long-term use of sulphonylurea: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Sulfonylurea induced beta-cell apoptosis in cultured human islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

The duration of sulfonylurea treatment is associated with β-cell dysfunction in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

β-cell function preservation after 3.5 years of intensive diabetes therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

The diabetic β-cell: hyperstimulated vs. hyperexcited

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Secondary consequences of beta cell inexcitability: identification and prevention in a murine model of K(ATP)-induced neonatal diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? No.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Haemodynamic and other effects of sulphonylurea drugs on the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Treating diabetes today: a matter of selectivity of sulphonylureas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

The cardiac sarcolemmal ATP-sensitive potassium channel as a novel target for anti-arrhythmic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Effects of sulfonylurea hypoglycemic agents and adenosine triphosphate dependent potassium channel antagonists on ventricular arrhythmias in patients with decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Impairment of myocardial protection in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Long-term effects of intensive glucose lowering on cardiovascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Glucose control and vascular complications in veterans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Are users of sulphonylureas at the time of an acute coronary syndrome at risk of poorer outcomes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Antidiabetic medications and the risk of colorectal cancer in patients with diabetes mellitus: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

A randomized trial of therapies for type 2 diabetes and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0473-5

Hepatic effect of sulfonylureas

21 January 2018

1 reference

12 December 2020

Sulfonylureas in insulin-dependent (type I) diabetes: evidence for an extrapancreatic effect in vivo

1 reference

12 December 2020

Population pharmacokinetics of glyburide in patients with well-controlled diabetes.

1 reference

12 December 2020

1 reference

12 December 2020

Sulfonylureas and the risk of myocardial infarction

1 reference

12 December 2020

Diabetic ketoacidosis in obese African-Americans

1 reference

12 December 2020

A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results

1 reference

12 December 2020

Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients

1 reference

12 December 2020

Glipizide increases plasma insulin but not C-peptide level after a standardized breakfast in type 2 diabetic patients

1 reference

12 December 2020

Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes

1 reference

12 December 2020

A novel mechanism of glipizide sulfonylurea action: decreased metabolic clearance rate of insulin

1 reference

12 December 2020

Prolonged sulfonylurea administration decreases insulin resistance and increases insulin secretion in non-insulin-dependent diabetes mellitus: evidence for improved insulin action at a postreceptor site in hepatic as well as extrahepatic tissues

1 reference

12 December 2020

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

12 December 2020

Decreased or increased insulin metabolism after glipizide in type II diabetes

1 reference

12 December 2020

The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic sulfonylurea drug Amaryl

1 reference

12 December 2020

The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of pheniformin therapy

1 reference

12 December 2020

Antidiabetic drugs and kidney disease--recommendations of the Swiss Society for Endocrinology and Diabetology

1 reference

12 December 2020

Influence of oral antidiabetic treatment on electrocardiac alterations induced by myocardial infarction

1 reference

12 December 2020

10.1007/S11892-014-0473-5

Identifiers

DOI

1 reference

PubMed ID

24563333

Dimensions Publication ID

30 August 2017

0 references

1 reference

PubMed ID

24563333